Skip to main content
Trusted advisor to healthcare practitioners · Est. 2016

Practice Operations · For practice managers

How to Verify FDA Section 361 Compliance for Biologics

Published November 18, 2026

Regulatory Qualification Criteria
Four Statutory Pillars

Under 21 CFR 1271.10(a), an HCT/P must simultaneously satisfy minimal manipulation, homologous use, no unauthorized combination, and systemic/metabolic restrictions to qualify as a Section 361 product.

Establishment Registration Renewal
Annual Requirement

Tissue establishments registered in the FDA eHCTERS database must update and validate their registration annually between November 15 and December 31.

Primary Compliance Burden
Shared Facility & Clinic Duty

While processing labs must follow Current Good Tissue Practice (cGTP), clinics are operationally responsible for verifying supplier standing, maintaining cold-chain storage, and logging recipient tracking records.

To verify FDA Section 361 compliance for biologics, medical practices must confirm that the manufacturing laboratory holds an active FDA Tissue Establishment Registration (FEI number) and that the specific product meets all four regulatory criteria under 21 CFR Part 1271.10(a), including minimal manipulation and homologous use. Additionally, procurement teams should obtain written confirmation from the FDA's Tissue Reference Group (TRG) or verify that the vendor's processing methods do not cross the regulatory threshold into Section 351 drug classification. Because the FDA does not issue pre-market approval letters for 361 products, the burden of due diligence rests heavily on the purchasing clinic and its distribution partners.

Understanding the Regulatory Landscape for HCT/Ps

For practice managers and administrators overseeing procurement in regenerative medicine, orthopedic, or aesthetic clinics, navigating the regulatory framework for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) is a primary risk-management responsibility. When adding biologics such as amniotic allografts, Wharton's Jelly, cord blood, or exosomes to a clinic's service line, distinguishing between Public Health Service (PHS) Act Section 361 and Section 351 products is essential.

Under the FDA framework, Section 351 products are regulated as drugs and biological products. They require an Investigational New Drug (IND) application for clinical study and a Biologics License Application (BLA) for commercial marketing. Conversely, Section 361 products are regulated exclusively under 21 CFR Part 1271 to prevent the introduction, transmission, and spread of communicable diseases. They do not require pre-market approval (PMA) or a BLA, provided they meet strict statutory criteria.

The most common pitfall in practice procurement is assuming that an "FDA Registered" certificate on a vendor's brochure equates to product approval. Registration merely means the facility has notified the FDA of its operations. Verifying true Section 361 compliance requires auditing both the facility's standing and the product's processing and intended use claims.

The Four Pillars of 21 CFR Part 1271.10(a)

Before auditing a supplier's paperwork, practice administrators must understand the four core criteria a product must simultaneously meet to qualify as a Section 361 HCT/P:

  1. Minimal Manipulation: For structural tissue (such as amniotic membrane or Wharton's Jelly connective tissue), processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics of the cells or tissues.
  2. Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor. Importantly, regulatory compliance here is determined by the labeling, advertising, and objective intent shown by the manufacturer and the distributor.
  3. No Combination with Other Articles: The HCT/P cannot be combined with another article, with limited exceptions for water, crystalloids, or sterilizing, preserving, or storage agents, provided these additions do not raise new clinical safety concerns.
  4. No Systemic Effect (With Specific Exceptions): Either the HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or, if it does have a systemic effect or depends on living cell metabolic activity, it is intended for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

If a product fails even one of these four criteria, it defaults to Section 351 status and cannot be legally marketed without a BLA or active IND.

Step-by-Step Checklist: How to Verify FDA Section 361 Compliance for Biologics

When onboarding a new manufacturer or evaluating your current supply chain, your operational team should execute a standardized compliance audit. Use the following checklist to build a defensible compliance file for every biologic SKU in your inventory:

  • Verify Active FDA Establishment Registration (eHCTERS): Obtain the manufacturer's Facility Establishment Identifier (FEI) number. Search the FDA's public Electronic Human Cell and Tissue Establishment Registration System (eHCTERS) database to confirm the registration is currently active, not expired or revoked, and specifically lists the tissue types you are purchasing.
  • Audit Inspection History and Enforcement Actions: Search the FDA Data Dashboard and Warning Letters database using the laboratory's legal corporate name and DBA. Confirm there are no unresolved Form 483 observations related to sterility, donor screening, or unapproved drug claims, and ensure the facility has not received an Untitled Letter or Warning Letter.
  • Review Processing SOP Summaries for Minimal Manipulation: Request a technical summary of the tissue processing methodology. Ensure that structural tissues are not subjected to enzymatic digestion, micronization, or aggressive mechanical grinding that destroys the native extracellular matrix architecture, as the FDA frequently views such alterations as more than minimal manipulation.
  • Audit Marketing Collateral for Homologous Use: Examine the manufacturer's package inserts, website, and brochures. Compliant 361 structural allografts should be described in terms of their structural function—such as serving as a protective covering, barrier, or cushioning scaffold. Avoid vendors whose marketing materials make systemic disease-treatment claims (e.g., claiming to cure osteoarthritis, reverse neuropathy, or treat autoimmune conditions).
  • Request Tissue Reference Group (TRG) Correspondence: Ask if the manufacturer has submitted their product profile to the FDA's Tissue Reference Group for a formal jurisdictional recommendation. While TRG letters are non-binding, a favorable TRG review provides strong documentation that the processing and labeling align with 361 criteria.
  • Verify Donor Eligibility and Infectious Disease Screening: Require a sample Certificate of Analysis (CoA) and donor eligibility summary. Under 21 CFR Part 1271 Subpart C, the facility must screen donors for relevant communicable disease agents and diseases (RCDADs) using FDA-licensed, approved, or cleared donor screening tests.
  • Confirm State Licensing and AATB Accreditation: Check whether the processing lab holds current American Association of Tissue Banks (AATB) accreditation and the required tissue bank licenses in stricter regulatory states (such as New York, California, Florida, and Maryland). In Texas, ensure your distribution partner holds an active medical device or wholesale distributor license, which you can review on our about page.

Clinical Perspective: Aligning Physician Protocols with Operational Compliance

While practice managers handle vendor vetting, contract negotiation, and inventory tracking, compliance is ultimately a shared responsibility between administration and the treating physicians. Whether your practice serves patients in orthopedics or aesthetics, clinical workflows must align with the regulatory framework of the products procured.

For the physician, the distinction between homologous structural use and unapproved systemic drug claims impacts chart documentation, informed consent, and patient education. Clinicians have broad latitude under the practice-of-medicine doctrine, which regulates how a licensed physician uses legally marketed products for individual patients. However, that autonomy relies on the underlying product being legally placed into interstate commerce to begin with.

Furthermore, if a clinic's external marketing—such as social media posts, landing pages, or patient seminars—promotes a Section 361 allograft as a systemic cure for degenerative diseases, both the clinic and the supplier create regulatory exposure. Physicians and medical directors should review all patient-facing educational materials alongside the practice manager to ensure that clinical terminology accurately reflects the product's role as a structural tissue allograft or autologous preparation, rather than an unapproved biological drug.

Operational Workflow and Cold-Chain Integrity

Compliance does not end once the vendor passes the initial paper audit. Under Good Tissue Practice (cGTP) standards, the receiving clinic must maintain product integrity and traceability from delivery to administration.

Practice managers should establish standard operating procedures (SOPs) for receiving biologics, verifying dry ice or cryogenic shipper temperatures upon arrival, and logging lot numbers into the electronic health record (EHR). Every allograft package includes a tissue tracking card or digital registration portal that must be completed and returned to the tissue bank once the product is implanted or applied. If your practice experiences a freezer malfunction or a shipping delay that compromises temperature thresholds, your vendor agreement should clearly outline quarantine protocols and replacement policies.

Working with an experienced medical distributor simplifies this administrative burden. Rather than auditing dozens of independent laboratories directly, clinics serving regenerative medicine doctors often partner with a licensed distributor that performs baseline regulatory vetting, consolidates cold-chain logistics, and maintains organized lot traceability records.

What This Means for Your Practice

Establishing a rigorous verification process protects your medical license, guards against financial loss from product seizures or recalls, and improves clinical consistency. To implement this framework immediately, take the following concrete actions:

  1. Build a Compliance Binder: Create a physical or digital folder for every biologic product in your clinic. Populate it with the manufacturer's current eHCTERS printout, AATB certificate, CLIA certificate, and a sample CoA.
  2. Audit Your Clinic's Website: Review your practice's public-facing pages and intake forms. Remove any language referring to "FDA-approved stem cells" when discussing Section 361 birth-tissue allografts, and ensure claims align with structural support and homologous function.
  3. Standardize Vendor Onboarding: Require all prospective sales representatives to complete your compliance checklist before presenting clinical or pricing proposals to your medical director.

If your administrative or clinical team is evaluating new regenerative service lines and wants to streamline vendor vetting, the team at Dallas Regenerative Solutions can help you navigate documentation, logistics, and product selection. Reach out through our contact page to schedule a consultation on compliant biologic sourcing for your practice.

Frequently asked questions

Does an FDA registration certificate mean a biologic product is FDA-approved?
No. An FDA Tissue Establishment Registration certificate only confirms that the facility has registered its operations and tissue types in the eHCTERS database under 21 CFR Part 1271. Section 361 HCT/Ps are regulated by rule to prevent communicable disease transmission and do not receive pre-market FDA approval letters like Section 351 biological drugs.
How can I check if a tissue bank is registered with the FDA?
Practice managers can verify a laboratory's registration status for free using the FDA's public Electronic Human Cell and Tissue Establishment Registration System (eHCTERS) online database. You can search by the establishment's legal name, location, or Facility Establishment Identifier (FEI) number to confirm whether the registration is active.
What is the difference between Section 361 and Section 351 biologics?
Section 361 biologics meet all four criteria of 21 CFR 1271.10(a)—including minimal manipulation and homologous use—and are regulated solely to prevent communicable disease without requiring pre-market approval. Section 351 biologics do not meet all four criteria (for example, cultured or enzymatically digested tissues) and are regulated as drugs requiring an Investigational New Drug (IND) application or Biologics License Application (BLA).
What is the FDA Tissue Reference Group (TRG)?
The Tissue Reference Group is a joint working group within the FDA (comprising representatives from CBER and CDRH) that provides manufacturers with informal, non-binding recommendations on whether a specific product qualifies as a Section 361 HCT/P. Requesting a copy of a vendor's TRG correspondence is a strong due diligence step during procurement.
What documentation should arrive with every biologic shipment to our clinic?
Every shipment should include a packing slip matching the purchase order, verification of cold-chain temperature integrity, a lot-specific Certificate of Analysis (CoA) or infectious disease screening clearance summary, the official package insert detailing storage and handling, and a tissue tracking card for patient traceability.

Bring regenerative medicine into your practice.

Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.

Request Consultation →